All In Biotech

Free tool

FAERS Monitor: Vyndamax

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212161 or its brand name (Vyndamax, Tafamidis). Reports on generic versions are filed under their own applications.

Reports

12,176

Serious

9,441

78% of reports

Hospitalization

3,429

Death reported

4,214

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death3,266
  • dyspnoea804
  • off label use661
  • cardiac failure638
  • fatigue585
  • fall479
  • atrial fibrillation397
  • dizziness357
  • malaise349
  • asthenia332
  • condition aggravated311
  • cardiac failure congestive308
  • hypoacusis303
  • weight decreased302
  • cardiac disorder288

Reports by year received

View as table
YearReports
20153
20161
20171
20184
2019123
2020644
20211,043
20221,755
20232,500
20242,545
20252,110
20261,447

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,983 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cardiac failureSignal63813.812.87,549
hypoacusisSignal30312.210.93,100
atrial fibrillationSignal3977.16.42,063
cardiac failure congestiveSignal3086.65.91,471
deathSignal3,2666.66.416,014
cardiac disorderSignal2885.34.81,010
fallSignal4792.52.3431
dyspnoeaSignal8042.52.3710
weight decreased3021.91.7123
condition aggravated3111.81.6104
asthenia3321.51.461
malaise3491.41.236
off label use6611.31.249
fatigue5851.31.241
dizziness3571.21.116

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.